World-Class, Turnkey Cro Facility Available Through Bankruptcy Sale with Full Suite of Lab Equipment & Intellectual Property
Ohio Pen/10301439

Trending...
NORTHBROOK, Ill., July 7, 2025 ~ Hilco Global, a leading financial services company, has announced that the bid deadline for the bankruptcy sale of a premier contract research organization (CRO) facility formerly occupied by AmplifyBio will be on August 15, 2025. The sale is being conducted under the direction of the U.S. Bankruptcy Court for the Southern District of Ohio, Case No. 25-52140 | In re: AmplifyBio, LLC.

This rare opportunity includes real estate, intellectual property and machinery and equipment, making it an attractive option for potential buyers looking to acquire a fully integrated CRO facility. The facility, located in West Jefferson, Ohio (Columbus MSA), was built in 2012 and boasts a total of 205,000 square feet. It features specialized lab space spanning 65,000 square feet, a state-of-the-art vivarium with 64 rooms covering 34,500 square feet and a fully equipped surgical suite. These features make it ideal for regulated and high-complexity research. Additionally, the property has sophisticated infrastructure and enhanced security measures in place to support sensitive operations.

The purpose-built laboratories at this facility are designed to support the development of pharmaceuticals, biotechnology products and medical devices. They offer capabilities in toxicology, safety pharmacology and bioanalytic characterization – all crucial components in advancing modern therapeutic innovations.

More on Ohio Pen
AmplifyBio was founded in 2021 with over $200 million in funding and quickly established itself as a leader in advanced therapy development. The company specialized in cutting-edge technologies such as gene editing, mRNA and T cell-based therapies and operated state-of-the-art facilities in both Ohio and California. AmplifyBio provided integrated pre-clinical R&D services as well as safety testing and GMP manufacturing services for various biopharma clients.

According to Joel Schneider, senior vice president at Hilco Real Estate Sales, "This sale presents an exceptional opportunity for a buyer to acquire a turnkey operation with Class-A laboratory and office space, tailored for a wide range of advanced research applications." Brent Bonham, senior managing director of Hilco Commercial Industrial, added, "The first-class, specialized facility includes an extensive list of highly sophisticated equipment, ideally suited for a broad spectrum of research. It presents a compelling opportunity for CROs and other research companies to acquire well-maintained infrastructure and lab components ready for immediate use."

In addition to the real estate and equipment, the sale also includes AmplifyBio's patent portfolio. David Peress, executive vice president with Hilco Streambank, stated that this portfolio offers a unique opportunity to acquire cutting-edge and clinically validated intellectual property in the fields of immunotherapy and cell engineering. The portfolio consists of 119 issued and pending patents covering non-viral gene editing, antigen-specific TCR identification and engineered T cell therapies. These innovations have broad applications in oncology and personalized medicine.

More on Ohio Pen
Interested bidders must submit their bids on or before August 15, 2025 at 12:00 p.m. (EST) based on the existing stalking horse Asset Purchase Agreement. This agreement can be found on Hilco Real Estate Sales' website for review and download. Those interested in participating in the sale process must review the court-approved "bid procedures" which are available on Hilco Real Estate Sales' website. For inquiries or to request an on-site inspection, please contact Chet Evans at (847) 418-2702.

For more information about this sale, including due diligence access and other critical details, interested parties can visit Hilco Real Estate Sales' Virtual Data Room. This is an excellent opportunity for companies in the research industry to acquire a fully equipped facility with advanced capabilities and cutting-edge intellectual property.
Filed Under: Business
Show All News | Report Violation

0 Comments

Latest on Ohio Pen